Stockreport

Inhibrx gets stockholders approval to sell INBRX-101 to Sanofi [Seeking Alpha]

Inhibrx Biosciences, Inc.  (INBX) 
PDF related to INBRX-101, a treatment of patients with alpha-1 antitrypsin deficiency. Immediately prior to the closing of the merger, all non-101 assets and liabilities, [Read more]